Brain cancer remains one of the most difficult diagnoses to face.
A Paris-based startup is hoping to change the odds for patients worldwide with a device the size of a grain of rice.
Robeauté recently secured $28 million in fresh funding to bring their microrobots to human trials by 2026. This technology promises to navigate deep inside the human brain to treat diseases that are currently unreachable.
A New Hope for Difficult Surgeries
Modern medicine has advanced rapidly in many areas. Yet neurosurgery faces the same limitations it has for decades.
Surgeons mostly use straight tools to reach tumors or affected areas. This linear approach forces doctors to cut through healthy brain tissue to reach a problem site deep inside the skull.
Robeauté is changing this fundamental rule of surgery.
The company has designed a microrobot capable of moving along curved paths through the brain.
This flexibility allows the device to avoid critical areas of the brain that control speech or movement. It creates a safer route to the target.
Robeauté microrobot device navigating brain tissue concept art
“It is about the ability to reach multiple sites through non-linear routes and to do so with the right level of accuracy. That fundamentally changes how neurosurgery is performed today,” says Joana Cartocci, co-founder and COO of Robeauté.
The recent Series A funding round highlights investor confidence in this bold vision. The $28 million injection will fuel the team’s expansion and prepare for critical clinical trials.
The Problem by the Numbers
| Statistic | Details |
|---|---|
| Global Impact | Over 1 billion people suffer from brain diseases. |
| New Cases | 350,000 people are diagnosed with primary brain cancer yearly. |
| Mortality | Approximately 250,000 patients die from these cancers annually. |
| Market Size | The drug market for brain diseases sits at around $72 billion. |
Moving Beyond Magnets and Gravity
Most medical microrobots currently in development rely on external forces.
Competitors typically use large magnets outside the patient’s head to pull a passive metal bead through the tissue. This method can be imprecise and difficult to scale for complex procedures.
Robeauté has taken a harder but more rewarding engineering path.
Their device is an active robot with its own propulsion system. It does not rely on external magnetic coils to move.
This autonomy gives surgeons precise control over the robot’s speed and trajectory.
The system consists of a carrier unit and a modular extension. The carrier handles the movement while the extension performs the medical task.
This modular design means the same robotic platform can perform different jobs.
- Biopsy: Taking tissue samples from deep tumors for analysis.
- Drug Delivery: Releasing medicine directly at the tumor site to avoid toxic side effects elsewhere.
- Data Collection: Using sensors to monitor brain activity from the inside.
- Stimulation: Implanting electrodes for deep brain stimulation therapies.
This versatility positions the device as a platform technology. It is not just a single tool but a system for various future treatments.
Inspired by Personal Tragedy and Space Tech
The story behind this innovation is deeply personal.
Bertrand Duplat founded the company after his mother was diagnosed with glioblastoma. This aggressive form of brain cancer is notoriously difficult to treat.
Duplat was not a doctor when he started. He was a robotics expert with experience at the European Space Agency and McGill University.
He spent 30 years designing robots for extreme environments like deep oceans and outer space.
He realized the human brain is another type of extreme environment that requires specialized engineering.
He teamed up with Joana Cartocci to handle operations. Together they built a company that bridges the gap between hard physics and delicate biology.
“He had been doing robotics for 30 years in extreme environments and decided to put that experience to good use,” Cartocci explains.
This unique combination of space-age engineering and medical need sets them apart from typical university spin-offs. They are building industrial-grade solutions from day one rather than just academic experiments.
Navigating the Regulatory Maze
Building the robot is only half the battle. Getting approval to put it inside a human head is the other half.
Robeauté has made the strategic decision to target the United States market first. The company has established a subsidiary in the US to work directly with the FDA.
Cartocci notes that the US regulatory system offers a more collaborative approach for novel devices.
“In the US, you co-create your regulatory strategy with the FDA,” Cartocci states.
Europe suffers from a fragmented regulatory landscape. Approval processes there can be slower and less interactive for groundbreaking tech.
By securing FDA approval first, the company hopes to create a blueprint that European regulators can eventually accept.
Current Roadmap for Robeauté:
- 2024-2025: Finalize preclinical testing and device iteration.
- 2025: Expand the engineering and regulatory teams in France and the US.
- Late 2026: Launch first-in-human clinical studies.
- Future: Commercial roll-out for biopsy and drug delivery applications.
The path forward is expensive and risky. However, the potential to save hundreds of thousands of lives drives the team forward.
Investors see the value in a platform that can unlock the brain. The ability to deliver drugs directly to a tumor could make existing medicines far more effective.
Current chemotherapy is often limited by the blood-brain barrier. This natural filter stops harmful substances from entering the brain but also blocks helpful drugs.
Robeauté bypasses this barrier completely by physically driving through it.
We are standing on the brink of a new era in medicine. The days of cutting open the skull for every procedure may be numbered.
Tiny, intelligent machines are coming to help us heal.
